Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict who will benefit from cladribine? new study aims to find out

NCT ID NCT05797740

Ongoing Knowledge-focused Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This observational study follows 367 adults with relapsing multiple sclerosis who are taking cladribine tablets (Mavenclad) in routine care. Researchers want to find out which patient characteristics predict how long people stay on the drug and how well it works. The goal is to help doctors personalize treatment decisions for MS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cladribine tablets (Mavenclad)
What this could lead to
If successful, this study could help doctors identify which multiple sclerosis patients are most likely to benefit from cladribine tablets, leading to more personalized treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

  • AHEPA University Hospital of Thessaloniki

    Thessaloniki, Greece

  • AZ Groeninge vzw

    Kortrijk, Belgium

  • Aiginiteio' Hospital

    Athens, Greece

  • Attikon

    Athens, Greece

  • CHU Sart Tilman

    Liège, Belgium

  • Centro Hospitalar Lisboa Norte Hospital de Santa Maria

    Lisbon, Portugal

  • Centro Hospitalar Universitário Lisboa Central - Hospital dos Capuchos

    Lisbon, Portugal

  • Centro Hospitalar de São João E. P. E.

    Porto, Portugal

  • Centro Hospitalar e Universitario de Coimbra

    Coimbra, Portugal

  • Evagelismos

    Athens, Greece

  • FN Hradec Králové

    Hradec Králové, Czechia

  • FN u sv. Anny Brno

    Brno, Czechia

  • Fakultni nemocnice Ostrava

    Ostrava, Czechia

  • General Hospital "Agios Andreas"

    Pátrai, Greece

  • General Hospital of Athens G.Gennimatas

    Thessaloniki, Greece

  • General Miliary Hospital of Athens "401"

    Athens, Greece

  • Interbalkan Hospital of Thessaloniki

    Thessaloniki, Greece

  • Medical Academy Neurology Clinic

    Poznan, Poland

  • Nemocnice Teplice

    Teplice, Czechia

  • NeuropsychiatrieHK

    Hradec Králové, Czechia

  • Oddział Kliniczny Neurologii, Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • St Luke's Clinic

    Thessaloniki, Greece

  • Szpital Kliniczny Nr 1 Pomorskiego Uniwersytetu Medycznego w Szczecinie

    Szczecin, Poland

  • UCL Saint Luc

    Brussels, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • University Hospital of Larissa

    Larissa, Greece

  • University of Ioannina - Neurology department

    Ioannina, Greece

  • University of Patras

    Pátrai, Greece

  • University of Thrace, Medical School - Neurology Department, Alexandroupoli

    Alexandroupoli, Greece

  • Zuyderland

    Sittard-Geleen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.